Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Journal of Geriatric Oncology|August 3, 2024
Functional status and quality of life in older patients with advanced esophageal squamous cell cancer receiving second-line nivolumab ± ipilimumab therapy: A post hoc analysis of the phase 2, multicenter RAMONA studyMoying Li, Nadja M Meindl-Beinker, Martin Maenz, et al.
The British Journal of Surgery|June 26, 2025
Evaluation of pathological complete response as a surrogate endpoint for overall survival in resectable oesophageal cancer: integrated analysis of individual patient data from phase III trialsJun Okui, Kengo Nagashima, Satoru Matsuda, et al.
Annals of Surgery|August 25, 2025
Recurrence-free Survival as a Surrogate Endpoint for Overall Survival in Resectable Esophageal Cancer: Integrated Analysis of Individual Patient Data From Phase III TrialsJun Okui, Satoru Matsuda, Kengo Nagashima, et al.
JAMA Oncology|June 26, 2020
Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 TrialJavier Cortés, Véronique Diéras, Sylvie Lorenzen, et al.
Oncology Research and Treatment|September 9, 2024
Paclitaxel/Ramucirumab versus Paclitaxel in 2nd-Line Therapy of Advanced Esophageal Squamous Cell Carcinoma: Randomized Phase II IKF-AIO-RAMOS TrialMagdalena K Scheck, Thorsten O Goetze, Thomas J Ettrich, et al.
BMC Cancer|March 1, 2020
High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08Martin Fehr, Hanne Hawle, Stefanie Hayoz, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|September 1, 2021
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trialCharles S Fuchs, Mustafa Özgüroğlu, Yung-Jue Bang, et al.
International Journal of Cancer|April 28, 2020
Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC)Sylvie Lorenzen, Jorge Riera Knorrenschild, Claudia Pauligk, et al.
Journal of the National Cancer Institute|October 11, 2013
Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysisXavier Paoletti, Koji Oba, Yung-Jue Bang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2021
Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10Zev A Wainberg, Charles S Fuchs, Josep Tabernero, et al.
Pageof 7